CurrentUnitedHealthcarePolicy CS079.S

Minimally Invasive Procedures for Gastric and Esophageal Diseases

UnitedHealthcare medical policy CS079.S defines coverage positions and evidence summaries for minimally invasive endoscopic and laparoscopic procedures for upper gastrointestinal diseases, including POEM, G-POEM, Z-POEM, and endoscopic therapies for GERD; it lists applicable CPT codes, definitions, related policies, and state-specific application exclusions.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases

Policy CodePolicy CS079.S

Change TypeClarifiedapplication scope updatesadministrative link updates

Effective DateDec 1, 2024

Next Review Date

Key ActionDocument diagnosis of Achalasia or Diffuse Esophageal Spasm when requesting POEM; other indications (e.g., Zenker's diverticulum) are considered not medically necessary.

SourceLink

POLICY UPDATE CHANGES

Updated reference link to reflect the current policy title for Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases.

Added language that this Medical Policy does not apply to Nebraska and North Carolina; refer to state-specific policy versions.

Added language that this Medical Policy does not apply to Idaho and Kansas; refer to state-specific policy versions.

Clarified that POEM is proven and medically necessary for Achalasia and Diffuse Esophageal Spasm and unproven/not medically necessary for other indications (e.g., Zenker's diverticula).

Added reference link to Medical Benefit Drug Policy titled Botulinum Toxins A and B Coverage Rationale.

2Proven Covered Indications (POEM)

Multiple

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy (CS079.S) addresses minimally invasive upper gastrointestinal procedures. POEM (per-oral endoscopic myotomy) is proven and medically necessary for Achalasia and Diffuse Esophageal Spasm, but is unproven and not medically necessary for other indications (for example, Zenker's diverticula). G-POEM (gastric POEM) is considered unproven and not medically necessary for treatment of gastroparesis. A range of endoscopic and device-based GERD therapies (including endoscopic plication/suturing, injection/implantation techniques, the LINX Reflux Management System, Stretta, TIF/EsophyX, MUSE, and other endoluminal approaches) and adjunctive technologies (e.g., EndoFLIP/FLIP) are described in the policy as unproven or not medically necessary for routine management of GERD due to insufficient or inconsistent evidence. The policy lists related medical policies (for example, Bariatric Surgery and Botulinum Toxins A and B) and provides CPT and device code references to support utilization and prior-authorization processes. State-specific application exclusions are noted: this policy does not apply to Nebraska, North Carolina, Idaho, and Kansas (refer to state-specific policy versions).

Policy metadata and key threshold

Effective date2024-12-01

Policy numberCS079.S

Scope summaryDefines coverage positions and evidence summaries for minimally invasive endoscopic and laparoscopic procedures for upper GI diseases (POEM, G-POEM, Z-POEM, endoscopic GERD therapies); lists CPT codes, definitions, related policies, and state-specific application exclusions.

Coverage stanceMixed — POEM proven/covered for Achalasia and Diffuse Esophageal Spasm; many GERD endoscopic therapies, G-POEM, Z-POEM and FLIP judged unproven/not medically necessary for most indications.

Threshold - follow-up duration concernsMost studies are short-term (6-12 months); long-term outcomes often not available or limited.

Medical-Necessity Criteria

Per Oral Endoscopic Myotomy (POEM) coverage

Covered when ALL of the following are met:

ALL of the following

Indication: Achalasia
POEM is proven and medically necessary for treating individuals with Achalasia
Indication: Diffuse Esophageal Spasm
POEM is proven and medically necessary for treating individuals with Diffuse Esophageal Spasm

POEM - Not medically necessary

POEM is unproven and not medically necessary for:

ANY of the following

Coverage Determinants & Evidence Elements

POEM (Per Oral Endoscopic Myotomy) coverage statement (from summary noted in revision history)

Policy-level coverage statements summarized in revision history (12/01/2024):

ALL of the following

POEM for Achalasia: POEM is proven and medically necessary for treating individuals with Achalasia
POEM for Diffuse Esophageal Spasm: POEM is proven and medically necessary for treating individuals with Diffuse Esophageal Spasm
POEM other indications not covered: POEM is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy

Coding

Referenced Procedure CodesCPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43999	Unlisted procedure, stomach.

Referenced device/regulatory identifiers (informational)mixed

P100049	FDA PMA number for LINX Reflux Management System.
510(k)	Clearance pathway cited for EsophyX2, MUSE, EndoFLIP and other endoluminal devices (general 510(k) references).

Provider Actions & Documentation Requirements

Documentation Required

Indication documentation for POEM

When requesting POEM, document the diagnosis (Achalasia or Diffuse Esophageal Spasm). Note that POEM for other indications (for example, Zenker's diverticula) is considered unproven and not medically necessary.

Affected code: 43497
Document diagnosis: Achalasia or Diffuse Esophageal Spasm
Other indications (e.g., Zenker's diverticulum) are not covered

Documentation Required

Documentation for GERD endoscopic therapies

For requests involving endoscopic or implantation therapies for GERD, document the clinical rationale and prior therapies. Policy classifies many endoscopic GERD therapies and implantation techniques as unproven and not medically necessary.

Affected codes: 43257, 43284, 43210, 43289, 43999
Document rationale and prior PPI/medical therapy
Policy notes many GERD endoscopic therapies are unproven/not medically necessary

Background & Definitions

This policy summarizes indications, definitions, and evidence for minimally invasive endoscopic and laparoscopic procedures of the upper GI tract. It reviews procedures including POEM (for achalasia and spastic esophageal disorders), Z-POEM (Zenker's diverticulum), and G-POEM (gastric per-oral endoscopic myotomy for gastroparesis), and evaluates other endoluminal GERD therapies and devices. The evidence review informed coverage positions (POEM covered for achalasia and diffuse esophageal spasm; G-POEM and many GERD endoscopic/device therapies considered unproven/not medically necessary). Related policies called out for additional context include Bariatric Surgery and Botulinum Toxins A and B.

Term	Definition
Achalasia	A primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, which results in impaired relaxation of the esophagogastric junction (EGJ), along with the loss of organized peristalsis in the esophageal body [American Society of Gastrointestinal Endoscopy (ASGE)].
Diffuse Esophageal Spasm	A rare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions that are of normal amplitude and accompanied by dysphagia (National Library of Medicine).
Gastroesophageal Reflux Disease (GERD)	A condition where the lower esophageal sphincter (LES) relaxes too often or weakens which allows stomach acid to flow backward (or reflux) into the esophagus [American College of Gastroenterology (ACG)].
Gastroparesis	A chronic disorder which means delayed stomach emptying without a blockage (ACG).
G-POEM	Gastric peroral endoscopic myotomy, endoscopic pyloromyotomy for refractory gastroparesis.
Stretta	Endoscopic radiofrequency energy treatment applied to the gastroesophageal junction for GERD.
TIF	Transoral incisionless fundoplication, endoscopic esophageal/gastric fundoplication (e.g., EsophyX).
GCSI	Gastroparesis Cardinal Symptom Index, patient-reported symptom score.
MSA	Magnetic sphincter augmentation (LINX) device implanted laparoscopically to augment LES function.
EndoFLIP/FLIP	Functional Lumen Imaging Probe measuring esophagogastric junction distensibility index (DI) and cross-sectional area.
POEM	Per-oral endoscopic myotomy, an endoscopic procedure to treat achalasia and certain esophageal motility disorders.
TIF / EsophyX	Transoral incisionless fundoplication using the EsophyX system for treatment of GERD.
LINX	Magnetic sphincter augmentation device (LINX Reflux Management System) for GERD.

Evidence Summary

The evidence base is mixed: many studies report short-term follow-up and observational designs, but randomized controlled trials and meta-analyses are available for several interventions. Notable RCTs and comparative trials exist for POEM (including noninferiority RCTs versus laparoscopic Heller myotomy), randomized sham-controlled data for G-POEM in severe gastroparesis, and randomized or controlled trials/meta-analyses for endoscopic antireflux procedures such as TIF/EsophyX, MUSE, and MSA/LINX. Systematic reviews and technology assessments highlight improvement in symptoms in many studies but emphasize short-term follow-up, heterogeneity across studies, and limited long-term objective outcome data.

Study / Source	Key finding / metric
Werner et al. (2019) randomized trial	POEM non-inferior to LHM at 2 years; clinical success 83.0% vs 81.7%; higher GERD incidence with POEM.
Hayes (2023) HTA	POEM has potential but unproven benefit vs LHM; additional fair-to-good quality studies needed.
Martinek et al. (2022) RCT (G-POEM)	G-POEM showed benefit vs sham at 6 months in severe/refractory gastroparesis; 15/21 vs 4/20 success; several serious adverse events reported.
Labonde et al. (2022)	GCSI decreased from 3.33 to 1.80 at 3 years after G-POEM.
Mohan et al. (2020) pooled review	Pooled GCSI change 3.4 to 1.8; 4-h GES change 49.9 to 20.6; ~76% clinical symptom reduction after G-POEM (707 patients reviewed).
Fass et al. (2017) Stretta meta-analysis	Stretta pooled HRQL decreased by -14.6 (p<0.001); 49% of baseline PPI users required PPIs at follow-up.
Zerbib et al. (2020) randomized sham-controlled Stretta	No significant difference between Stretta and sham at 24 and 48 weeks for days without heartburn, PPI use; did not demonstrate efficacy for PPI-refractory GERD in this RCT.
McCarty et al. (2018) EsophyX pooled data	Included 32 articles (1,390 patients); symptom improvements and reduced PPI use reported; 88 patients required subsequent surgery.
Håkansson RCT (TIF)	TIF2 clinical remission at 6 months: 59% remission in TIF2 vs sham; longer remission time (197 vs 107 days); small RCT n=44.
MSA trials and meta-analyses	PPI discontinuation achieved in 81-91% in cohorts; RCT showed superiority to double-dose PPI for regurgitation; notable rates of postoperative dysphagia and device removals reported.
Bell et al. (2019/2020) MSA RCT	MSA controlled regurgitation in 96% vs 19% with PPIs; transient dysphagia in 28% of MSA patients.
Stojilkovic et al. (2023) G-POEM review	Clinical success (≥1 point GCSI decrease) achieved in 92.8% at 1 year, 91.5% at 2 years; adverse events in 62/835 patients; long-term adverse events not well documented.

Revision History

02/01/2026Administrative

Updated reference link to reflect the current policy title for Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases.

10/01/2025Administrative

Added language that this Medical Policy does not apply to Nebraska and North Carolina; refer to state-specific policy versions.

06/01/2025Administrative

Added language that this Medical Policy does not apply to Idaho and Kansas; refer to state-specific policy versions.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases

Policy CodePolicy CS079.S

Change TypeClarifiedapplication scope updatesadministrative link updates

Effective DateDec 1, 2024

Next Review Date

Key ActionDocument diagnosis of Achalasia or Diffuse Esophageal Spasm when requesting POEM; other indications (e.g., Zenker's diverticulum) are considered not medically necessary.

SourceLink

On This Page

Endoscopic and other minimally invasive therapies for GERD

Unproven and not medically necessary for treating GERD:

ALL of the following

Endoscopic therapies for GERD
Unproven and not medically necessary due to insufficient evidence of efficacy
Injection/implantation techniques: Injection or implantation techniques for GERD
Unproven and not medically necessary due to insufficient evidence
LINX Reflux Management System
Considered unproven/not established for long-term safety and effectiveness per policy discussion
GERDx: Endoluminal therapy with GERDx™ (not FDA approved)
Investigational, unproven, and not medically necessary as it has not received FDA approval
FLIP diagnostic use: Functional lumen imaging probe (FLIP) technology is unproven and not medically necessary for diagnosing Achalasia
EndoFLIP/FLIP evidence insufficient to support routine diagnostic use

Documentation Required

Patient selection documentation for MSA

When documenting patient selection for magnetic sphincter augmentation (MSA), include objective reflux testing, hiatal hernia size, absence of advanced Barrett's esophagus, and BMI considerations, since trials and guidance commonly required these criteria.

Objective reflux testing (e.g., abnormal pH/DeMeester)
Hiatal hernia size limits (commonly < 3 cm; some devices/ trials use ≤ 2–3 cm)
Exclude advanced Barrett's esophagus (e.g., LA Grade C/D)
Document BMI and note higher BMI (eg, >35) may predict poorer outcomes

Prior Authorization

Prior authorization likely required for device procedures

Prior authorization is likely required for device-based antireflux procedures. Payers should request documentation of prior medical therapy, objective testing, and anatomic findings and ensure eligibility criteria used in trials are met.

Documentation of prior PPI therapy and response
Objective reflux testing results (eg, pH/DeMeester or equivalent)
Anatomic documentation (hiatal hernia size on endoscopy/imaging)
Information demonstrating trial eligibility criteria (eg, absence of advanced esophagitis or Barrett's)